of CRF.
Results. The patients had significantly (P Ͻ 0.05) reduced Bone mineral density (BMD) measured by dual-energy BMD in the spine (Ϫ6.3%), the femur (Ϫ12.1%), the forearm x-ray absorptiometry (DEXA) has proven to be a strong (Ϫ5.7%), and the total body (Ϫ4.2%) as compared with the control subjects. Dividing the patients into quartiles according predictor of bone strength in healthy persons and in osteoto GFR revealed that BMD decreased with the gradual decline porotic patients [4, 5] , and DEXA is a precise, rapid, in renal function at all the measured skeletal sites, but was most and noninvasive procedure to detect osteopenia [6, 7] . gators have found reduced bone mass [8] [9] [10] [11] [12] [13] [14] . Studies on Serum PTH and serum P levels increased, whereas serum Ca ϩϩ BMD in patients with mild to moderate CRF are few. and 1,25-dihydroxyvitamin D decreased. BMD Z-scores of the Most of the cohorts are small, and the inclusion criteria femur and of the forearm correlated to the biochemical markers differ in terms of the underlying renal diseases and the and to PTH (P Ͻ 0.05 to P Ͻ 0.0001). The biochemical markers all showed strong correlations to PTH, also when corrected severity of the renal impairment [11, [15] [16] [17] [18] . Further- of chronic renal failure, as estimated from reduced BMD and measuring at different parts of the skeleton and using elevated levels of PTH and from the biochemical markers of both bone formation and bone resorption.
(AP), and the vitamin D status. However, currently, biomarkers. Group 1 (GFR 6 to 26 ml/min) represented patients with the most advanced stages of renal failure. chemical markers of bone turnover are being evaluated in the diagnosis and monitoring of metabolic bone disease Groups 2 (GFR 27 to 47 ml/min) and 3 (GFR 47 to 69 ml/min) represented patients with moderate and mild [18] . Among these, osteocalcin, carboxy terminal propeptide of type I collagen (PICP), and bone-specific AP renal impairment, respectively, whereas group 4 (GFR 71 to 110 ml/min) was established from a group of pa-(BAP) reflect bone formation, whereas carboxy-terminal telopeptide of type I collagen (ICTP) reflects bone retients with a serum creatinine level above the upper normal range (130 mol/liter), but who had a GFR sorption.
The usefulness of these new potential markers of bone within the normal range when the creatinine clearance was measured. Group 5 represented the control subjects. turnover in patients with renal failure has not been clarified, although a few studies have shown a good correla-
The patients in group 1 had a lower body mass index (BMI) of 24 Ϯ 4 kg/m 2 compared with the other patient tion between some of the bone markers and some of the histomorphometric parameters of bone turnover in groups, in which BMI was 27 Ϯ 5 kg/m 2 . There was no difference in age between the groups. In groups 1 patients on maintenance dialysis [19, 20] .
This study was designed further to examine the frethrough 3, females constituted 29, 35, and 35% of the patients, respectively, whereas only 14% of the patients quency and severity of the skeletal demineralization in patients with predialysis CRF by measurements of the in group 4 were women. Twenty-two patients with insulin-dependent diabetes BMD in different skeletal regions (trabecular and cortical bone) and by evaluation of the serum levels of osteowere included and equally distributed between groups 1 through 3, whereas there were fewer diabetic patients calcin, PICP, BAP, and ICTP in patients with mild to moderate CRF as compared with these measures of bone in group 4. The control group of healthy subjects (N ϭ 89, group 5) metabolism in a healthy control group.
was chosen to match the patient group with regards to gender, age (within 5 years for women and within 10 METHODS years for men), and body weight (Ϯ5%) in order to The study design was cross-sectional. Patients were eliminate the effect of these three major determinants recruited from the outpatient clinics at three Danish on the BMD, which are unrelated to the renal disease County Hospitals. All hospital records of patients fol- [21, 22] . Healthy subjects were recruited among hospital lowed at the nephrological departments were evaluated, staff along with their relatives and friends. The study and patients with a serum creatinine value above 130 was approved by the regional committee of ethics. All mol/liter (upper normal range) were invited to participarticipants gave their written informed consent. pate, unless exclusion criteria were met. Exclusion criteBone density measurements ria included: patients with acute renal failure, patients receiving maintenance dialysis, kidney transplanted paBone mineral density of the lumbar spine (L2 through tients, patients who currently were taking or who within L4) in the anteroposterior projection, the femoral neck, the last five years had been taking medication known to the distal forearm, and the total body were determined influence bone metabolism [such as corticosteroids, other by DEXA on a QDR2000 bone densitometer (Hologic immunosuppressive agents, hormone replacement therInc., Waltham, MA, USA) expressed as exact values in apy (HRT), vitamin D analogs, anticoagulants, or lithium], g/cm 2 and as Z scores, which represent the BMD value and bedridden patients. Thus, several patients with glonormalized for age-and sex-matched mean, or as T merulonephritis (immunosuppressive therapy) and sevscores that refer to the young adult reference mean calcueral female patients (HRT) had to be omitted. Four hunlated from the manufacturer's database of 400 males and dred hospital records were evaluated. One hundred and 900 females. Coefficients of variation at our clinic are fifty patients were contacted, and 128 agreed to partici-0.9% at the lumbar spine, 1.9% at the femoral neck, pate. Fifteen had to be excluded because of the presence 1.0% at the distal forearm, and 0.8% for the whole-body of one or more exclusion criteria, and therefore, 113 pascan. tients (31 females of whom 16 were postmenopausal and Biochemical measurements 82 males), all Caucasian, were included. None of the patients were on a protein-restricted diet, and none received Blood samples were drawn after an overnight fast bephosphate binders at the time of the investigation. tween 8 and 10 a.m. Urine was collected for 24 hours in The demographic data of the patients are presented order to calculate the creatinine clearance rates. Serum in Table 1 . The patients were stratified into quartiles samples for determination of biochemical bone markers according to the glomerular filtration rate (GFR) in orwere stored at Ϫ80ЊC until analysis. GFRs were assessed der to examine the influence of increasing impairment by a 24-hour creatinine clearance value. Serum Ca ϩϩ and serum P were measured using routine laboratory of the renal function on BMD and the biochemical bone Abbreviations are: BMI, body mass index; HKD, hypertensive kidney disease; PKD, polycystic kidney disease; Miscellaneous, congenital malformations, Alport syndrome, gout-and drug-induced nephropathy, unknown cause. Values are means Ϯ sd or N (%).
procedures. All biochemical bone markers were meabetween groups. Bivariate correlations were performed in log-transformed data. A forward stepwise regression sured by the Bone and Mineral Research Group (Aarhus University Hospital, Aarhus, Denmark).
analysis was used to detect predictors of BMD [26] . Statistical analyses were performed using the software Intact PTH was measured by a radioimmunoassay (Allegro Intact PTH, IRMA; Nichol's Institute, San Juan, Stat View 4.5 (Abacus Concepts, Berkeley, CA, USA). Capistrano, CA, USA). The intra-assay coefficient of variation (CV) was 2.6%, and the interassay CV was 5.8%. RESULTS Serum 25-hydroxyvitamin D was measured by a radioBone mineral density immunoassay (Incstar Kit 60160; Incstar Corp., Stillwater, MN, USA) after acetonitrile extraction. Intra-assay Bone mineral density was reduced at all areas of the skeleton examined, when all the patients were compared and interassay CVs were 8 and 15%, respectively. Serum 1,25-dihydroxyvitamin D was extracted by acetonitrile, with the matched control group. The difference in BMD at the site of the lumbar spine was Ϫ6.3% (0.98 Ϯ 0.02 purified through a C18-OH reverse phase column, and finally measured by a radioimmunoassay (Nichols-Kit vs. 1.04 Ϯ 0.02 g/cm 2 , P Ͻ 0.05); the femoral neck, Ϫ12.1% (0.72 Ϯ 0.01 vs. 0.82 Ϯ 0.02, P Ͻ 0.0001); the distal 40-6040). The intra-assay and interassay CVs were 6.5 and 13.2%.
forearm, Ϫ5.7% (0.68 Ϯ 0.01 vs. 0.72 Ϯ 0.01, P Ͻ 0.05); and the total body, Ϫ4.2% (1.08 Ϯ 0.01 vs. 1.12 Ϯ 0.01, Serum cross-linked ICTP was measured by an equilib-P Ͻ 0.05). rium radioimmunoassay from Orion Diagnostics (Espoo, When the patients were separated into quartiles acFinland). Intra-assay and interassay CVs were 5 and 6% cording to the degree of renal failure, it was found that [23] . The PICP was measured by an equilibrium RIA BMD decreased in relationship to the decrease in GFR (Orion Diagnostics), with an intra-assay and interassay at all measured sites, as shown in Figure 1 . CV of 3 and 5%, respectively. Serum AP was measured The greatest differences between the patient groups spectrophotometrically using serum nitrophenylphosand the control group were found at the site of the femur phate as the substrate according to recommendations where significant differences in between patient groups from the Scandinavian Committee on Enzymes [24] . In-(P Ͻ 0.05), as well as between patients and control subtra-assay and interassay CVs were 1.8 and 3%, respecjects (P Ͻ 0.05), were found. At the levels of the lumbar tively. BAP was measured spectrophotometrically in the spine, the distal forearm and the total body significant supernatant after lectin precipitation. The intra-assay differences (P Ͻ 0.05 to P Ͻ 0.001) were identified beand interassay CVs were 8 and 25%. Serum osteocalcin tween the lowest GFR quartile (group 1) and the control was determined by a radioimmunoassay using rabbit antigroup (group 5). serum against bovine bone gla protein. The intra-assay
The prevalence of osteoporosis as defined by the and interassay CVs were 5 and 10% [25] .
World Health Organization (a T score of less than Ϫ2.5) Statistical analysis was significantly increased (P Ͻ 0.0001) in the patient group (30%) as compared with the control group (10%) Students unpaired t-test was used to evaluate the differences between patients and control subjects. Analysis of variand even more so in the patients with the more advanced stages of renal failure (Table 2) . ance or the Kruskal-Wallis test was used to test differences chronic renal disease before 30 years of age compared to patients with Symbols are: (᭹) group 1, mean GFR 16 ml/min; (᭡) group 2, mean a debut when they are 30 years or older. Symbols are: () early debut; GFR 39 ml/min; () group 3, mean GFR 58 ml/min; (᭜) group 4, mean ( ) later debut. *P Ͻ 0.05, by Student's t-test. GFR 83 ml/min; (᭺) group 5, control group, mean GFR 144 ml/min. *P Ͻ 0.05, **P Ͻ 0.001, and ***P Ͻ 0.0001, by ANOVA. Values are given in percentages of the respective patient groups (group 1, mean GFR 16; group 2, 39; group 3, 58; and group 4, 86 ml/min). A T-score Ͻ Ϫ2.5 defines osteoporosis according to WHO criteria.
a P Ͻ 0.05 group 1 compared to group 3; b P Ͻ 0.05; c P Ͻ 0.0001, all patients compared to controls
The possible impact of the age at onset of CRF on Parameters of calcium homeostasis BMD was examined by dividing all the patients into two
Patients with predialysis CRF exhibited several abnorgroups according to the onset of the renal disease before mal parameters involved in the bone metabolism, as or after the age of 30 years, which is the age of peak compared with their matched controls. bone mass [27] . The results were expressed as Z scores As shown in Figure 4 , serum PTH and P levels in- (Fig. 2 ) in order to account for the differences in current creased significantly (P Ͻ 0.05) with the decline in GFR, age and sex between the two groups. Patients with an whereas serum Ca ϩϩ decreased (P Ͻ 0.05), with the early debut of the renal disease had significantly reduced lowest circulating levels found in patients with the most BMD as compared with patients with a debut of the severe degree of renal impairment. The serum levels of disease later in life at the sites of the lumbar spine, the 1,25-dihydroxyvitamin D were also reduced (P Ͻ 0.05) femoral neck, and the distal forearm.
in the advanced stages of CRF. When dividing the study group according to whether Biochemical markers of bone turnover the patients had insulin-dependent diabetes mellitus (IDDM) or other kidney diseases, it was found that the The mean serum levels of the different biochemical combination of impaired renal function and IDDM enmarkers of bone formation (osteocalcin, PICP, and BAP), hanced the risk of low BMD, as illustrated in Figure 3 .
as well as of bone resorption (ICTP), all increased with The BMD Z scores of the femoral neck and of the distal the more advanced stages of renal impairment. Signififorearm were significantly reduced in the group of pacantly increased (P Ͻ 0.05) serum values of osteocalcin, tients with IDDM, as compared with patients with differ-BAP, PICP, and ICTP were found in the group of paent chronic renal diseases, whereas the BMD of the tients with the most advanced stages of renal failure when compared with the control group (Fig. 5) . lumbar spine was not significantly reduced. Bivariate correlations between the biochemical bone markers and PTH and GFR are shown in Table 3 . A strong positive correlation (P Ͻ 0.0001) was demonstrated between PTH and the bone markers osteocalcin, BAP, and ICTP, whereas the correlation to PICP was not significant. A significant inverse correlation (P Ͻ 0.0001) was found between PTH and GFR. Each of the measured bone markers was negatively correlated to GFR (P Ͻ 0.05 to P Ͻ 0.001). To further examine the relationship between PTH and the bone markers, a partial correlation analysis was performed. The correlation between PTH and the bone markers remained significant after the adjustment for the influence of GFR: osteocalcin, r ϭ 0.89, P Ͻ 0.0001; BAP, r ϭ 0.69, P Ͻ 0.0001; ICTP, r ϭ 0.64, P Ͻ 0.0001; and PICP, r ϭ 0.27, P Ͻ 0.05.
In order to examine the effect of the serum levels of PTH on BMD, patients were divided into three groups according to the degree of secondary hyperparathyroidism: Serum PTH increased to more than two times above normal limits (120 pg/ml), serum PTH between 60 and 120 pg/ml, and serum PTH within normal reference range (Ͻ60 pg/ml). A negative association between the degree of secondary hyperparathyroidism and BMD was found at the sites of the lumbar spine, the hip, and the total body, but not in the arm, and the patients who had the most severe degrees of secondary hyperparathyroidism had the most reduced levels of BMD as compared with the patients with PTH levels within the normal reference range (Fig. 6) .
To examine the importance of the different risk factors for reduced BMD, a forward stepwise regression analysis was performed with BMD of the hip given in Z scores as the dependent variable and BMI, creatinine clearance rates, serum PTH, and the duration of and age at onset of the renal disease as independent variables. BMI and compared to control subjects. Symbols are: (᭹) group 1, mean GFR 16 creatinine clearance rates were the two variables that ml/min; (᭡) group 2, mean GFR 39 ml/min; () group 3, mean GFR 58 significantly predicted BMD, accounting for 19% of the ml/min; (᭜) group 4, mean GFR 83 ml/min; (᭺) group 5, control group, mean GFR 144 ml/min. *P Ͻ 0.05, Kruskal-Wallis test.
variation (R 2 ϭ 0.19, P Ͻ 0.001) in BMD, and each of the . Serum PTH and duration and age at onset of the renal disease were not significant predictors in this type of analysis.
DISCUSSION
In this group of 113 patients with predialysis CRF, BMD was reduced in the axial, as well as in the appendicular skeleton, indicating that both cortical bone and trabecular bone were affected. The prevalence of overt osteoporosis (T-score Ͻ Ϫ2.5) was found to be increased when compared with healthy sex-, age-, and weightmatched controls. The study included patients ranging from mild to severe degrees of renal failure, and the decrease in BMD was most pronounced in patients with the lowest levels of GFR. Debut of the renal disease renal failure divided into quartiles according to GFR compared to normal control subjects. Symbols are: (᭹) group 1, mean GFR 16 ml/ before skeletal maturity was reached and diabetic nemin; (᭡) group 2, mean GFR 39 ml/min; () group 3, mean GFR 58 phropathy further increased the risk of low BMD. In a ml/min; (᭜) group 4, mean GFR 83 ml/min; (᭺) group 5, control group, multivariate analysis, GFR and BMI were the strongest mean GFR 144 ml/min. *P Ͻ 0.05, Kruskal-Wallis test.
predictors of BMD.
Secondary HPT, reduced levels of serum Ca ϩϩ and serum 1,25-dihydroxyvitamin D, and increased serum levels of P were evident in the patients with moderate to severe degrees of renal failure.
The biochemical markers of bone turnover (osteocalcommence at an early stage of renal failure. Bianchi et al reported that patients with predialysis CRF have cin, ICTP, PICP, and BAP) all exhibited elevated serum levels in the patient groups with the more advanced reduced BMD levels that correlate to the reduction in GFR [16] . However, they concluded that only cortical stages of renal failure corresponding to the degree of secondary HPT. Adjusting the correlation between PTH bone was affected, which is in disagreement with the present results showing that trabecular and cortical bone and the different biochemical bone markers for the influence of GFR did not change the results, indicating are equally affected in these uremic patients. Reasons for this discrepancy might be due to different scanning that the increased levels of the different biochemical bone markers might indeed represent increased bone techniques and different patient groups. It has been proposed that the duration of the renal turnover caused by the secondary hyperparathyroidism and not just caused by retention of the substances. The disease might be an important risk factor for low BMD. In dialysis patients, some studies showed a negative correpresence of advanced secondary HPT (serum PTH Ͼ 120 pg/ml) was associated with decreased BMD.
lation between time on dialysis and BMD [11, 12] , whereas others failed to prove such a correlation [8, 9, 37] . In those Whether BMD measurement is an appropriate tool in the diagnosis and/or monitoring of renal bone disease studies, the duration of the predialysis phase of the renal disease was not considered, which from our investigation is still a matter of debate. DeVita et al concluded from a study comparing histomorphometric results to DEXA seems to be of importance when evaluating renal bone disease. Further support for this argument was supplied results that the sensitivity of BMD measurements was poor [20] . Furthermore, Malluche and Faugere pointed by Heaf, Hielsen, and Mogensen, who, in a group of patients followed from predialysis to dialysis stages of out that DEXA measurements did not separate the different types of ROD (high turnover, low turnover, and their renal disease, found that some of the patients with the lowest BMD at the time when dialysis treatment was mixed uremic osteodystrophy), which may be essential for the choice of treatment [28] . However, the severity commenced actually gained bone mass within one year, perhaps because of the improvement in the uremic state of the symptoms of ROD may not correlate with the histological changes, as some patients have severely abor because of supplementation with 1,25-dihydroxy-vitamin D [8] . normal bone histology and no symptoms and vice versa [2] . Patients with reduced bone mass are at great risk of Therefore, when considering the initiation and the early stages of ROD, the predialysis period seems as experiencing fractures, the most severe consequence of ROD, and this part of the population at risk can be important as the end-stage period. It has been suggested that the underlying renal disease detected by DEXA measurements. This investigation has shown that even in predialysis stages of CRF, a may have some influence on the severity of the renal bone disease. Cundy et al, in a study on histomorphomesubstantial proportion of the patients, patients who would not be considered for bone biopsies in the daily tric changes in predialysis patients, demonstrated that tubulointerstitial renal diseases affect the skeleton more clinic, showed signs of disturbed bone metabolism as measured by noninvasive methods.
than glomerulovascular diseases and suggested that this might be due to more pronounced changes of the calcium Specific biochemical markers of bone turnover have been studied extensively over the last decade, but the homeostasis caused by the former group of diseases [38] . This is in opposition to the results of others in which actual concept in the bone research field is that these biochemical markers are of no certain diagnostic use in patients with diabetic nephropathy [15, 39] have been found to have increased risk of renal bone disease. It is the single patient, but might be of some use in following the results of clinical trials [29, 30] . The reasons for the not clear, however, whether the diabetic state or the renal complication is the most important factor, as others limitation in the daily clinical use are a substantial intraindividual variability [31] and a poor correlation between have shown that IDDM by itself is a risk factor for reduced BMD [40, 41] , whereas patients with NIDDM the markers and the rate of bone loss [32] .
Only a few publications exist on the use of biochemical have normal or even increased BMD [42] . Furthermore, Moorhead et al found that patients with polycystic kidbone markers in patients with predialysis CRF. In those, it was concluded that the retention of the bone markers ney disease were less susceptible to bone changes than patients with other renal diseases [43] . osteocalcin and ICTP caused by the reduced renal clearance [23, 33] introduced an error, which made it difficult In this study, IDDM but not NIDDM was found to be a risk factor for low BMD, whereas the patient groups to interpret the results. The clearance of PICP and BAP is not by the kidney, but takes place in the liver, which with other renal diseases each comprised numbers of patients that were too limited to be evaluated separately. may render these markers more suitable in the evaluation of renal bone disease [34, 35] .
Reduced BMD has been demonstrated in children and adolescents with CRF [44] . This is in accordance with The results of this study support the findings from histomorphometric studies [3, 8, 36] that skeletal changes the results of this investigation, where it appears to be of importance whether chronic renal disease occurs before skeleton, a state that may or may not have been established long enough to have caused substantial bone loss. skeletal maturity is reached, suggesting that patients with a debut of the renal disease before adulthood may not Despite the obvious adverse effects on BMD of the different aspects of CRF that were evaluated in this achieve an adequate peak bone mass and, therefore, have an increased risk of developing osteopenia when study, a considerable variation in BMD exists within this group of patients. The contribution of other factors such factors causing accelerated bone loss appear.
The secondary hyperparathyroidism and low serum as heritage, hormonal status, and physical activity is possible. The advantage of a longitudinal study as opposed levels of 1,25-dihydroxyvitamin D, which become evident in end-stage renal failure, have been shown to be to the cross-sectional design used in this study is therefore obvious, and long-term prospective studies with initiated at early stages of the renal disease [45, 46] , which corroborate with the results of this study.
skeletal symptoms and fragility fractures as efficacy endpoints are needed to validate the predictive value of The elevated levels of the biochemical bone markers found in this study are in accordance with results from these noninvasive methods in relationship to symptomatic bone disease in patients with CRF. a few other studies performed in predialysis patients in which the bone formation markers osteocalcin [47] , BAP
In conclusion, a state of high bone turnover resulting in reduced bone density is present early in the course of [48] , and PICP [34] have been evaluated. Elevated serum levels of the bone markers have been reported consis-CRF (GFR 6 to 70 ml/min), as estimated from reduced BMD levels, elevated serum PTH, reduced 1,25-dihytently in patients receiving maintenance dialysis [31, [48] [49] [50] [51] [52] , but in these patients with none or very little remaining droxyvitamin D levels, and the elevated levels of biochemical markers of both bone formation (osteocalcin, kidney function, the accumulation of substances may be pronounced.
PICP, BAP) and bone resorption (ICTP). This study further demonstrates that useful information on the bone The apparent lower serum concentrations of PICP and BAP in the patients with incipient renal failure (group 4) status can be obtained by using noninvasive methods, such as BMD measurements and biochemical markers may be coincidental, as there was no significant difference from the values of the control group, or it may be of skeletal formation and resorption in patients with predialysis CRF. due to the fact that this group consisted almost exclusively of male subjects, who may have lower values of bone markers than female subjects in the age groups ACKNOWLEDGMENTS mainly represented in this study [18] . 
